Nkarta Q4 net loss widens

Nkarta

25/03/2026 20:14

Overview

US biotechnology firm's Q4 net loss widened, basic EPS was -$0.37

Company ended 2025 with $295.1 mln in cash

Outlook

Nkarta expects its current cash and cash equivalents to fund its current operating plan into 2029

Result Drivers

R&D SPENDING - Net loss driven by continued investment in NKX019 clinical trials and related research activities

Company press release: ID:nGNX2WJvKD

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.37
Q4 Net Income
-$27.4 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Nkarta Inc is $11.00, about 436.6% above its March 24 closing price of $2.05

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)